The link above shows all the companies with hats in the ring. There are some heavy hitters, but with NVAX's ability to produce a vaccine in 90 days (and subsequent ability to mass produce thereafter), they should stand a very strong chance at funding.
Remember, they produced a very effective Ebola vaccine in 90 days in response to the epidemic, but they were "late" to the game because other companies had already been working on Ebola prior to that huge outbreak in Africa.
I think that they won't move anything along further than the initial stages without funding from gov't because they have their eyes on RSV studies.
News 
Market Data 
Discover 
